魏文嵩
[摘要]意图 探討表柔比星联合紫杉醇脂质体的新辅佐化疗办法医治三阴性乳腺癌的临床作用。办法 选取2015年6月～2016年6月我院收治的80例三阴性乳腺癌患者作为研讨目标，随机分为调查组和对照组，各40例。对照组独自给予表柔比星新辅佐化疗，调查组选用紫杉醇脂质体、表柔比星联合新辅佐化疗。比较两组医治前后的肿瘤直径、乳腺癌易感基因（BRCA1）水平、叉头框蛋白A1（FOXA1）水平、临床效果及医治过程中的不良反应发生率。成果 调查组的总有功率为82.50%，明显高于对照组的70.00%，差异有统计学含义（P<0.05）。两组的不良反应发生率比较，差异无统计学含义（P>0.05）。两组医治后的肿瘤直径、BRCA1和FOXA1水均匀低于医治前，差异有统计学含义（P<0.05）。调查组医治后的肿瘤直径、BRCA1和FOXA1水平明显优于对照组医治后，差异有统计学含义（P<0.05）。定论 选用紫杉醇脂质体、表柔比星联合新辅佐化疗医治三阴性乳腺癌安全可靠，不添加不良反应，患者的耐受性较好，具有较高的临床使用价值。
[关键词]三阴性乳腺癌；表柔比星；紫杉醇脂质体；新辅佐化疗；临床效果
[中图分类号] R737.9 [文献标识码] A [文章编号] 1674-4721（2016）12（b）-0065-03
Effects of the neoadjuvant chemotherapy of the combination application of Epirubicin and Lipid Paclitaxel in the treatment of triple negative breast cancer
WEI Wen-song
Department of the Third Galactophore，the Third Hospital of Nanchang City，Jiangxi Province，Nanchang 330009，China
[Abstract]Objective To explore the clinical efficacy of the neoadjuvant chemotherapy of the combination application of Epirubicin and Lipid Paclitaxel in the treatment of triple negative breast cancer （TNBC）.Methods 80 patients with TNBC in our hospital from June 2015 to June 2016 were selected and randomly divided into the observation group and the control group，40 cases in each group.The control group was given simple neoadjuvant chemotherapy of Epirubicin.The observation group was given neoadjuvant chemotherapy of the combination application of Epirubicin and Lipid Paclitaxel.The tumor diameter，breast cancer susceptibility gene （BRCA1） level，fork-box protein A1 （FOXA1） level before and after treatment and clinical efficacy，the incidence rate of adverse reaction were compared between the two groups.Results The total effective rate of the observation group was 82.50%，which was higher than 70.00% of the control group，with significant difference （P<0.05）.There was no significant difference in the incidence rate of adverse reaction between the two groups（P>0.05）.The tumor diameter，the level of BRCA1 and FOXA1 after treatment in the two group was lower than that before treatment，with significant difference （P<0.05）.The tumor diameter，the level of BRCA1 and FOXA1 after treatment in the observation group was better than that in the control group，with significant difference （P<0.05）.Conclusion The neoadjuvant chemotherapy of the combination application of Epirubicin and Lipid Paclitaxel in the treatment of TNBC is safe and reliable，with no increase of adverse reaction，and the patients have a higher degree of tolerance while being treated.It is highly significant in clinical application.
